Recursion Pharmaceuticals (NASDAQ: RXRX)
Recursion Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Recursion Pharmaceuticals Company Info
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
News & Analysis
Is Recursion Pharmaceuticals a Millionaire Maker?
This is the only biotech stock to attract an investment from artificial intelligence (AI) giant Nvidia.
What Companies Does Nvidia Own?
Top Biotech ETFs to Buy Now
Here are the five best biotech ETFs to invest in right now.
Where Will Recursion Pharmaceuticals Be in 5 Years?
Could investing in this stock be an underrated way to profit from the rapidly expanding AI industry?
The Biotech Stock That's Too Risky for Most Investors
It's unclear how long it's going to be before this company has a product to sell.
How to Invest in First Trust Nasdaq Artificial Intelligence and Robotics ETF (ROBT)
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
This AI company isn't yet living up to the hype.
1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell
There might be better artificial intelligence (AI) stocks out there to buy.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.